$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000032001719000053 Filed on May 09, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$0.00	$0.00	$300.0K
YoY Change		-100.0%	-96.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.358M	$2.554M	$2.897M
YoY Change	9.88%	-11.84%	7.04%
% of Gross Profit
Research & Development	$2.988M	$2.038M	$2.262M
YoY Change	40.74%	-9.9%	-39.29%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$90.00K
YoY Change	-75.0%	-77.78%	-10.0%
% of Gross Profit
Operating Expenses	$5.346M	$4.592M	$5.159M
YoY Change	25.23%	-10.99%	-19.8%
Operating Profit	-$5.346M	-$4.592M	-$5.159M
YoY Change	25.23%	-10.99%	-19.8%
Interest Expense	$0.00	$0.00	$3.000K
YoY Change	-100.0%	-100.0%	-98.11%
% of Operating Profit
Other Income/Expense, Net	$209.0K	$227.0K	$175.0K
YoY Change	8.85%	29.71%	-186.07%
Pretax Income	-$5.137M	-$4.370M	-$4.984M
YoY Change	25.99%	-12.33%	-24.89%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$5.140M	-$4.367M	-$4.984M
YoY Change	26.07%	-12.38%	-49.11%
Net Earnings / Revenue			-1661.33%
Basic Earnings Per Share
Diluted Earnings Per Share	-$494.7K	-$435.7K	-$520.9K
COMMON SHARES
Basic Shares Outstanding	10.38M shares	9.950M shares	9.553M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.66M	$38.37M	$48.58M
YoY Change	-33.12%	-21.02%	304.87%
Cash & Equivalents	$11.75M	$14.42M	$21.60M
Short-Term Investments	$21.90M	$23.95M	$26.98M
Other Short-Term Assets	$1.200M	$1.300M	$5.800M
YoY Change	0.0%	-77.59%	-13.43%
Inventory
Prepaid Expenses
Receivables			$144.3K
Other Receivables			$0.00
Total Short-Term Assets	$34.82M	$39.65M	$54.53M
YoY Change	-32.46%	-27.29%	148.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$130.0K	$148.0K	$178.1K
YoY Change	32.49%	-16.9%	-98.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.402M	$1.494M	$1.434M
YoY Change	216.62%	4.18%	118.78%
Total Long-Term Assets	$1.532M	$1.642M	$2.187M
YoY Change	183.22%	-24.93%	-91.78%
TOTAL ASSETS
Total Short-Term Assets	$34.82M	$39.65M	$54.53M
Total Long-Term Assets	$1.532M	$1.642M	$2.187M
Total Assets	$36.35M	$41.29M	$56.72M
YoY Change	-30.22%	-27.2%	16.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$559.0K	$553.0K	$866.8K
YoY Change	10.55%	-36.21%	-75.77%
Accrued Expenses	$5.153M	$4.548M	$6.998M
YoY Change	-2.76%	-35.01%	38.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$100.0K
YoY Change			-96.87%
Total Short-Term Liabilities	$5.712M	$5.101M	$7.957M
YoY Change	-1.99%	-35.9%	-65.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.016M	$1.729M	$3.444M
YoY Change	-63.69%	-49.79%	745.59%
Total Long-Term Liabilities	$1.016M	$1.729M	$3.444M
YoY Change	-63.69%	-49.79%	63.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.712M	$5.101M	$7.957M
Total Long-Term Liabilities	$1.016M	$1.729M	$3.444M
Total Liabilities	$6.728M	$6.830M	$11.40M
YoY Change	-22.0%	-40.09%	-63.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$407.5M	-$402.4M	-$386.8M
YoY Change	4.27%	4.04%	-6.61%
Common Stock	$10.00K	$10.00K	$9.575K
YoY Change	2.72%	4.44%	6.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$708.0K	$708.0K	$707.6K
YoY Change	0.05%	0.05%	0.0%
Treasury Stock Shares	11.08K shares	11.08K shares	11.08K shares
Shareholders Equity	$29.89M	$34.73M	$45.59M
YoY Change
Total Liabilities & Shareholders Equity	$36.35M	$41.29M	$56.72M
YoY Change	-30.22%	-27.2%	16.87%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$5.140M	-$4.367M	-$4.984M
YoY Change	26.07%	-12.38%	-49.11%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$90.00K
YoY Change	-75.0%	-77.78%	-10.0%
Cash From Operating Activities	-$4.720M	-$5.486M	-$6.299M
YoY Change	-19.73%	-12.91%	-37.56%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$9.000K
YoY Change		-100.0%	-87.08%
Acquisitions
YoY Change
Other Investing Activities	$2.010M	$8.740M	-$1.180M
YoY Change	9.24%	-840.68%	1080.0%
Cash From Investing Activities	$2.010M	$8.741M	-$1.189M
YoY Change	9.24%	-835.16%	594.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	40.00K	$870.0K	-$72.00K
YoY Change	-75.0%	-1308.33%	-100.95%
NET CHANGE
Cash From Operating Activities	-4.720M	-$5.486M	-$6.299M
Cash From Investing Activities	2.010M	$8.741M	-$1.189M
Cash From Financing Activities	40.00K	$870.0K	-$72.00K
Net Change In Cash	-2.670M	$4.125M	-$7.560M
YoY Change	-31.19%	-154.56%	179.23%
FREE CASH FLOW
Cash From Operating Activities	-$4.720M	-$5.486M	-$6.299M
Capital Expenditures	$0.00	$0.00	$9.000K
Free Cash Flow	-$4.720M	-$5.486M	-$6.308M
YoY Change	-19.73%	-13.03%	-37.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2019Q1	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2019Q1	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	USD
CY2019Q1	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	USD
CY2018Q1	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2018Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	30000	shares
CY2019Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	30000	shares
CY2017Q2	clbs	Funding Of Grant Award Cash Received FundingOfGrantAwardCashReceived	5700000	USD
CY2018Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1718000	USD
CY2019Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1635000	USD
CY2018Q4	clbs	Market Capitalization Used In Net Operating Loss Analysis MarketCapitalizationUsedInNetOperatingLossAnalysis	124500000	USD
CY2019Q1	clbs	Milestone Payment On Grant Award Cash Received MilestonePaymentOnGrantAwardCashReceived	1900000	USD
CY2017	clbs	Net Operating Loss Analysis Annual Limitation NetOperatingLossAnalysisAnnualLimitation	3000000	USD
CY2019Q1	clbs	Number Of Offices Under Operating Leases NumberOfOfficesUnderOperatingLeases	2	office
CY2018Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2019Q1	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2018Q1	clbs	Progress Payment On Grant Award Cash Received ProgressPaymentOnGrantAwardCashReceived	300000	USD
CY2019Q1	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	30000	shares
CY2019Q1	clbs	Warrants Canceled WarrantsCanceled	0	shares
CY2019Q1	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2019Q1	clbs	Warrants Expired WarrantsExpired	0	shares
CY2019Q1	clbs	Warrants Granted WarrantsGranted	0	shares
CY2019Q1	clbs	Warrants Vested WarrantsVested	30000	shares
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0.00
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	5.89
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.00
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	0.00
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0.00
CY2018Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	5.89
CY2019Q1	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	5.89
CY2019Q1	clbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	5.89
CY2019Q1	clbs	Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest	P3Y11M12D
CY2017	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P4Y2M9D
CY2019Q1	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P3Y11M12D
CY2019Q1	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P3Y11M12D
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10382232	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Caladrius Biosciences, Inc.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4548000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4857000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	762000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	553000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4857000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4548000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	436433000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	437850000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	147000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	547000	USD
CY2018Q4	us-gaap	Assets Assets	44580000	USD
CY2019Q1	us-gaap	Assets Assets	41288000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	44106000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	39646000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	32000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37850000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	36139000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis	36139000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	36121000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	0	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37818000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	36121000	USD
CY2018Q4	us-gaap	Cash Cash	5064000	USD
CY2019Q1	us-gaap	Cash Cash	12175000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10299000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14424000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	37818000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	36121000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34168000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10299000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26608000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14424000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7560000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4125000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2018Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1758000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	908000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9865735	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10393312	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9865735	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10393312	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4983000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4353000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4985000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4351000	USD
CY2018Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2019Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2018Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	2583000	USD
CY2019Q1	us-gaap	Customer Advances Current CustomerAdvancesCurrent	2583000	USD
CY2019Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	241000	USD
CY2018Q1	us-gaap	Grants Receivable GrantsReceivable	8600000	USD
CY2017Q1	us-gaap	Grants Receivable GrantsReceivable	12200000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-2000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	2000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-90000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-91000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	3000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	147000	USD
CY2019Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	547000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1505000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	27000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	236000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	411000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	403000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	428000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	7126000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	6830000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44580000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41288000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5619000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5101000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	32754000	USD
CY2019Q1	us-gaap	Marketable Securities MarketableSecurities	23946000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	-272000	USD
CY2019Q1	us-gaap	Minority Interest MinorityInterest	-270000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-72000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	870000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1189000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8741000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6299000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5486000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4982000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4367000	USD
CY2019Q1	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	-62000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	227000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	5159000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4592000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5159000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4592000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1264000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1184000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09625
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	516000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	661000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	309000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1494000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-31000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1507000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1729000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	178000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	227000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	45000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	130000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24144000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16264000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1053000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1276000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1000000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22964000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	25005000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-4984000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-4365000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	148000	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2262000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2038000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-397977000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-402406000	USD
CY2018Q4	us-gaap	Retention Payable RetentionPayable	0	USD
CY2019Q1	us-gaap	Retention Payable RetentionPayable	396000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2897000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2554000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	127688	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	123564	shares
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	351000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	612000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	103000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	417000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	37726000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	34728000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50189000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45317000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37454000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34458000	USD
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2019Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	708000	USD
CY2019Q1	us-gaap	Treasury Stock Value TreasuryStockValue	708000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9557000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10027000	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risks</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash, cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</font></div></div>

Files In Submission

Name	View Source	Status
0000320017-19-000053-index-headers.html	Edgar Link	pending
0000320017-19-000053-index.html	Edgar Link	pending
0000320017-19-000053.txt	Edgar Link	pending
0000320017-19-000053-xbrl.zip	Edgar Link	pending
clbs-10qx20190331.htm	Edgar Link	pending
clbs-20190331.xml	Edgar Link	completed
clbs-20190331.xsd	Edgar Link	pending
clbs-20190331_cal.xml	Edgar Link	unprocessable
clbs-20190331_def.xml	Edgar Link	unprocessable
clbs-20190331_lab.xml	Edgar Link	unprocessable
clbs-20190331_pre.xml	Edgar Link	unprocessable
clbs-ex311_20190331xq1.htm	Edgar Link	pending
clbs-ex312_20190331xq1.htm	Edgar Link	pending
clbs-ex321_20190331xq1.htm	Edgar Link	pending
clbs-ex322_20190331xq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2019 Q2 Form 10-Q Financial Statement

#000032001719000053 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2019 Q2 Form 10-Q Financial Statement

#000032001719000053 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta